Research graph
References from Decoupling Neuroprotection from MAO Inhibition via Indane-to-Azaindane Bioisosteric Replacement of Rasagiline. Local targets link to admitted publications; unresolved targets remain external evidence.
Role of dopamine in the pathophysiology of Parkinson’s disease
10.1186/s40035-023-00378-6 · 2023 · External reference
The role of oxidative stress in Parkinson’s disease
10.3233/jpd-130230 · 2013 · External reference
The therapeutic potential of monoamine oxidase inhibitors
10.1038/nrn1883 · 2006 · External reference
Monoamine oxidase inactivation: From pathophysiology to therapeutics
10.1016/j.addr.2008.06.002 · 2008 · External reference
Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: Relevance to DATATOP
10.1007/978-3-7091-9113-2_32 · 1990 · External reference
Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B
10.1038/sj.bjp.0703826 · 2001 · External reference
(R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: Highly selective and potent inhibitors of monoamine oxidase B
10.1007/978-3-7091-6499-0_30 · 1998 · External reference
Rasagiline in Parkinson’s disease: A review based on meta-analysis of clinical data
10.1016/j.phrs.2013.05.005 · 2013 · External reference
Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases
10.1016/j.mad.2004.08.023 · 2005 · External reference
Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial
10.1016/s0140-6736(05)71083-7 · 2005 · External reference
Rasagiline (TVP-1012): A new selective monoamine oxidase inhibitor for Parkinson’s disease
10.1016/j.amjopharm.2006.12.001 · 2006 · External reference
Rasagiline: A review of its use in the management of Parkinson’s disease
10.2165/00003495-200767120-00006 · 2007 · External reference
Impact of newer pharmacological treatments on quality of life in patients with Parkinson’s disease
10.2165/00023210-200822070-00003 · 2008 · External reference
The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline
10.1111/j.1471-4159.2009.06542.x · 2010 · External reference
Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline
10.5607/en.2013.22.1.1 · 2013 · External reference
Enantiopure synthesis of 7-(1-pyrindanyl)propargyl ethers as rasagiline analogues via chemical or enzymatic resolution of 1-pyrindan-7-ol
10.1039/c5ra24868j · 2015 · External reference
Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class
10.1021/jm031087c · 2004 · External reference
Neuroprotection by propargylamines in Parkinson’s disease: Suppression of apoptosis and induction of prosurvival genes
10.1016/s0892-0362(02)00221-0 · 2002 · External reference
Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition
10.1002/jnr.20350 · 2005 · External reference
Neuroprotective and neuro-restorative effects of minocycline and rasagiline in a zebrafish 6-hydroxydopamine model of Parkinson’s disease
10.1016/j.neuroscience.2017.10.018 · 2017 · External reference
Rasagiline and selegiline suppress calcium efflux from mitochondria by PK11195-induced opening of mitochondrial permeability transition pore: A novel anti-apoptotic function for neuroprotection
10.1007/s00702-015-1398-0 · 2015 · External reference
Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan
10.1046/j.1471-4159.2002.01047.x · 2002 · External reference
Effect of long-term treatment with rasagiline on cognitive deficits and related molecular cascades in aged mice
10.1016/j.neurobiolaging.2015.05.009 · 2015 · External reference
Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity
10.1016/j.pneurobio.2010.06.008 · 2010 · External reference
Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022
10.1007/978-3-7091-6301-6_11 · 2000 · External reference
Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022
10.1111/j.1749-6632.2001.tb03641.x · 2001 · External reference
Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson’s disease: A systematic review
10.1007/s10072-019-04050-8 · 2020 · External reference
The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing
10.1096/fj.03-0078fje · 2003 · External reference
Rasagiline
10.2165/00002512-200522010-00006 · 2005 · External reference
Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline
10.1016/s0047-6374(01)00391-8 · 2002 · External reference
Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase
10.1163/156856003765764344 · 2003 · External reference
Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine
10.1096/fj.05-3794fje · 2005 · External reference
Binding of rasagiline-related inhibitors to human monoamine oxidases: A kinetic and crystallographic analysis
10.1021/jm0506266 · 2005 · External reference
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
10.3389/fphar.2016.00340 · 2016 · External reference
Synthesis of new propargylated 1-pyrindane derivatives as rasagiline analogues
10.1055/s-0032-1318492 · 2013 · External reference
Synthesis and characterization of 1-pyrindane derivatives as rasagiline analogues
10.1016/j.cdc.2016.10.001 · 2016 · External reference
Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia
10.2165/00003495-199754010-00013 · 1997 · External reference
Practical asymmetric synthesis of a selective endothelin a receptor (ETA) antagonist
10.1021/ol016601s · 2001 · External reference
Synthesis and evaluation of a series of aminocyanopyridines as antimicrobial agents
10.1007/s00044-009-9273-x · 2011 · External reference
5-Substituted [1]pyrindine derivatives with antiproliferative activity
10.1016/j.ejmech.2009.11.028 · 2010 · External reference
Receptor-based virtual ligand screening for the identification of novel CDC25 phosphatase inhibitors
10.1021/ci700313e · 2008 · External reference
Performance of chiral tetracarbonylmolybdenum pyrindanyl amine complexes in catalytic olefin epoxidation
10.1016/j.jorganchem.2018.01.003 · 2018 · External reference
Dopamine autoreceptor agonists as potential antipsychotics. 3. 6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine
10.1021/jm00113a010 · 1991 · External reference
Synthesis of 6,7-dihydro-5H-cyclopenta[b]pyridin-5-one analogues through manganese-catalyzed oxidation of the CH2 adjacent to pyridine moiety in water
10.1039/c4gc02471k · 2015 · External reference
Superacid-catalyzed intramolecular cyclization reaction of arylcyanopropionate: Geminal substitution effect on superelectrophilicity
10.1021/jo800674h · 2008 · External reference
Selective electrochemical oxygenation of alkylarenes to carbonyls
10.1021/acs.orglett.1c02651 · 2021 · External reference
Electrochemical benzylic oxidation of C–H bonds
10.1039/c8cc08768g · 2019 · External reference
Development of a flow photochemical aerobic oxidation of benzylic C–H bonds
10.1021/acs.orglett.8b00540 · 2018 · External reference
Iron-catalyzed oxidative functionalization of C(sp3)–H bonds under bromide-synergized mild conditions
10.1039/c9cc03939b · 2019 · External reference
The rearrangement of substituted pyridine N-oxides with acetic anhydride1.2
10.1021/jo01061a037 · 1961 · External reference
Rearrangements of N-oxides. A novel synthesis of pyridyl carbinols and aldehydes
10.1021/ja01634a026 · 1954 · External reference
The mixture of ″ecstasy″ and its metabolites is toxic to human SH-SY5Y differentiated cells at in vivo relevant concentrations
10.1007/s00204-013-1120-7 · 2014 · External reference
Neurotoxicity of ″ecstasy″ and its metabolites in human dopaminergic differentiated SH-SY5Y cells
10.1016/j.toxlet.2012.11.015 · 2013 · External reference
Chapter 15 - Paraquat-induced Neurodegeneration: a Model of Parkinson’s Disease Risk Factors
10.1016/b978-0-12-374028-1.00015-4 · 2008 · External reference
Rotenone, Paraquat, and Parkinson’s Disease
10.1289/ehp.1002839 · 2011 · External reference
Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells
10.1016/j.neuint.2010.06.017 · 2010 · External reference
Stereoselective activity of 1-propargyl-4-styrylpiperidine-like analogues that can discriminate between monoamine oxidase isoforms A and B
10.1021/acs.jmedchem.9b01886 · 2020 · External reference
N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer’s agents
10.1016/j.bmc.2016.11.032 · 2017 · External reference
Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition
10.1002/jnr.20350 · ExternalCitation · doi-reference
Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022
10.1007/978-3-7091-6301-6_11 · ExternalCitation · doi-reference
(R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: Highly selective and potent inhibitors of monoamine oxidase B
10.1007/978-3-7091-6499-0_30 · ExternalCitation · doi-reference
Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: Relevance to DATATOP
10.1007/978-3-7091-9113-2_32 · ExternalCitation · doi-reference
Synthesis and evaluation of a series of aminocyanopyridines as antimicrobial agents
10.1007/s00044-009-9273-x · ExternalCitation · doi-reference
The mixture of ″ecstasy″ and its metabolites is toxic to human SH-SY5Y differentiated cells at in vivo relevant concentrations
10.1007/s00204-013-1120-7 · ExternalCitation · doi-reference
Rasagiline and selegiline suppress calcium efflux from mitochondria by PK11195-induced opening of mitochondrial permeability transition pore: A novel anti-apoptotic function for neuroprotection
10.1007/s00702-015-1398-0 · ExternalCitation · doi-reference
Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson’s disease: A systematic review
10.1007/s10072-019-04050-8 · ExternalCitation · doi-reference
Chapter 15 - Paraquat-induced Neurodegeneration: a Model of Parkinson’s Disease Risk Factors
10.1016/b978-0-12-374028-1.00015-4 · ExternalCitation · doi-reference
Monoamine oxidase inactivation: From pathophysiology to therapeutics
10.1016/j.addr.2008.06.002 · ExternalCitation · doi-reference
Rasagiline (TVP-1012): A new selective monoamine oxidase inhibitor for Parkinson’s disease
10.1016/j.amjopharm.2006.12.001 · ExternalCitation · doi-reference
N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer’s agents
10.1016/j.bmc.2016.11.032 · ExternalCitation · doi-reference
Synthesis and characterization of 1-pyrindane derivatives as rasagiline analogues
10.1016/j.cdc.2016.10.001 · ExternalCitation · doi-reference
5-Substituted [1]pyrindine derivatives with antiproliferative activity
10.1016/j.ejmech.2009.11.028 · ExternalCitation · doi-reference
Performance of chiral tetracarbonylmolybdenum pyrindanyl amine complexes in catalytic olefin epoxidation
10.1016/j.jorganchem.2018.01.003 · ExternalCitation · doi-reference
Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases
10.1016/j.mad.2004.08.023 · ExternalCitation · doi-reference
Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells
10.1016/j.neuint.2010.06.017 · ExternalCitation · doi-reference
Effect of long-term treatment with rasagiline on cognitive deficits and related molecular cascades in aged mice
10.1016/j.neurobiolaging.2015.05.009 · ExternalCitation · doi-reference
Neuroprotective and neuro-restorative effects of minocycline and rasagiline in a zebrafish 6-hydroxydopamine model of Parkinson’s disease
10.1016/j.neuroscience.2017.10.018 · ExternalCitation · doi-reference
Rasagiline in Parkinson’s disease: A review based on meta-analysis of clinical data
10.1016/j.phrs.2013.05.005 · ExternalCitation · doi-reference
Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity
10.1016/j.pneurobio.2010.06.008 · ExternalCitation · doi-reference
Neurotoxicity of ″ecstasy″ and its metabolites in human dopaminergic differentiated SH-SY5Y cells
10.1016/j.toxlet.2012.11.015 · ExternalCitation · doi-reference
Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline
10.1016/s0047-6374(01)00391-8 · ExternalCitation · doi-reference
Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial
10.1016/s0140-6736(05)71083-7 · ExternalCitation · doi-reference
Neuroprotection by propargylamines in Parkinson’s disease: Suppression of apoptosis and induction of prosurvival genes
10.1016/s0892-0362(02)00221-0 · ExternalCitation · doi-reference
Stereoselective activity of 1-propargyl-4-styrylpiperidine-like analogues that can discriminate between monoamine oxidase isoforms A and B
10.1021/acs.jmedchem.9b01886 · ExternalCitation · doi-reference
Selective electrochemical oxygenation of alkylarenes to carbonyls
10.1021/acs.orglett.1c02651 · ExternalCitation · doi-reference
Development of a flow photochemical aerobic oxidation of benzylic C–H bonds
10.1021/acs.orglett.8b00540 · ExternalCitation · doi-reference
Receptor-based virtual ligand screening for the identification of novel CDC25 phosphatase inhibitors
10.1021/ci700313e · ExternalCitation · doi-reference
Rearrangements of N-oxides. A novel synthesis of pyridyl carbinols and aldehydes
10.1021/ja01634a026 · ExternalCitation · doi-reference
Dopamine autoreceptor agonists as potential antipsychotics. 3. 6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine
10.1021/jm00113a010 · ExternalCitation · doi-reference
Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class
10.1021/jm031087c · ExternalCitation · doi-reference
Binding of rasagiline-related inhibitors to human monoamine oxidases: A kinetic and crystallographic analysis
10.1021/jm0506266 · ExternalCitation · doi-reference
The rearrangement of substituted pyridine N-oxides with acetic anhydride1.2
10.1021/jo01061a037 · ExternalCitation · doi-reference
Superacid-catalyzed intramolecular cyclization reaction of arylcyanopropionate: Geminal substitution effect on superelectrophilicity
10.1021/jo800674h · ExternalCitation · doi-reference
Practical asymmetric synthesis of a selective endothelin a receptor (ETA) antagonist
10.1021/ol016601s · ExternalCitation · doi-reference
The therapeutic potential of monoamine oxidase inhibitors
10.1038/nrn1883 · ExternalCitation · doi-reference
Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B
10.1038/sj.bjp.0703826 · ExternalCitation · doi-reference
Synthesis of 6,7-dihydro-5H-cyclopenta[b]pyridin-5-one analogues through manganese-catalyzed oxidation of the CH2 adjacent to pyridine moiety in water
10.1039/c4gc02471k · ExternalCitation · doi-reference
Enantiopure synthesis of 7-(1-pyrindanyl)propargyl ethers as rasagiline analogues via chemical or enzymatic resolution of 1-pyrindan-7-ol
10.1039/c5ra24868j · ExternalCitation · doi-reference
Electrochemical benzylic oxidation of C–H bonds
10.1039/c8cc08768g · ExternalCitation · doi-reference
Iron-catalyzed oxidative functionalization of C(sp3)–H bonds under bromide-synergized mild conditions
10.1039/c9cc03939b · ExternalCitation · doi-reference
Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan
10.1046/j.1471-4159.2002.01047.x · ExternalCitation · doi-reference
Synthesis of new propargylated 1-pyrindane derivatives as rasagiline analogues
10.1055/s-0032-1318492 · ExternalCitation · doi-reference
The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing
10.1096/fj.03-0078fje · ExternalCitation · doi-reference
Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine
10.1096/fj.05-3794fje · ExternalCitation · doi-reference
The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline
10.1111/j.1471-4159.2009.06542.x · ExternalCitation · doi-reference
Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022
10.1111/j.1749-6632.2001.tb03641.x · ExternalCitation · doi-reference
Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase
10.1163/156856003765764344 · ExternalCitation · doi-reference
Role of dopamine in the pathophysiology of Parkinson’s disease
10.1186/s40035-023-00378-6 · ExternalCitation · doi-reference
Rotenone, Paraquat, and Parkinson’s Disease
10.1289/ehp.1002839 · ExternalCitation · doi-reference
Rasagiline
10.2165/00002512-200522010-00006 · ExternalCitation · doi-reference
Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia
10.2165/00003495-199754010-00013 · ExternalCitation · doi-reference
Rasagiline: A review of its use in the management of Parkinson’s disease
10.2165/00003495-200767120-00006 · ExternalCitation · doi-reference
Impact of newer pharmacological treatments on quality of life in patients with Parkinson’s disease
10.2165/00023210-200822070-00003 · ExternalCitation · doi-reference
The role of oxidative stress in Parkinson’s disease
10.3233/jpd-130230 · ExternalCitation · doi-reference
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
10.3389/fphar.2016.00340 · ExternalCitation · doi-reference
Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline
10.5607/en.2013.22.1.1 · ExternalCitation · doi-reference
